Development of acute kidney injury during continuous infusion of vancomycin in septic patients
PURPOSE: Few data are available on the occurrence of renal failure during continuous infusion of vancomycin in critically ill patients.
METHODS: We reviewed the data of all patients admitted to the intensive care unit (ICU) between January 2008 and December 2009 in whom vancomycin was given as a continuous infusion for more than 48 h in the absence of renal replacement therapy. We collected data on the doses of vancomycin and blood concentrations during therapy. Acute kidney injury (AKI) was defined as a daily urine output <0.5 ml/kg/h and/or an increase in the serum creatinine of ≥0.3 mg/dl from baseline levels during vancomycin therapy or within 72 h after its discontinuation. Multivariable logistic regression analysis was performed to identify predictors of AKI.
RESULTS: Of 207 patients who met the inclusion criteria, 50 (24 %) developed AKI. These patients were more severely ill, had lower creatinine clearance at admission, were more frequently exposed to other nephrotoxic agents, had a longer duration of therapy, and had higher concentrations of vancomycin during the first 3 days of treatment (C(mean)). The C(mean) was independently associated with early AKI (within 48 h from the onset of therapy) and the duration of vancomycin administration with late AKI.
CONCLUSIONS: AKI occurred in almost 25 % of critically ill patients treated with a continuous infusion of vancomycin. Vancomycin concentrations and duration of therapy were the strongest variables associated with the development of early and late AKI during therapy, respectively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Infection - 41(2013), 4 vom: 08. Aug., Seite 811-20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cianferoni, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6Q205EH1VU |
|---|
| Anmerkungen: |
Date Completed 22.10.2013 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s15010-013-0460-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM226545385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM226545385 | ||
| 003 | DE-627 | ||
| 005 | 20231224071655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-013-0460-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0755.xml |
| 035 | |a (DE-627)NLM226545385 | ||
| 035 | |a (NLM)23572272 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cianferoni, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of acute kidney injury during continuous infusion of vancomycin in septic patients |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2013 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Few data are available on the occurrence of renal failure during continuous infusion of vancomycin in critically ill patients | ||
| 520 | |a METHODS: We reviewed the data of all patients admitted to the intensive care unit (ICU) between January 2008 and December 2009 in whom vancomycin was given as a continuous infusion for more than 48 h in the absence of renal replacement therapy. We collected data on the doses of vancomycin and blood concentrations during therapy. Acute kidney injury (AKI) was defined as a daily urine output <0.5 ml/kg/h and/or an increase in the serum creatinine of ≥0.3 mg/dl from baseline levels during vancomycin therapy or within 72 h after its discontinuation. Multivariable logistic regression analysis was performed to identify predictors of AKI | ||
| 520 | |a RESULTS: Of 207 patients who met the inclusion criteria, 50 (24 %) developed AKI. These patients were more severely ill, had lower creatinine clearance at admission, were more frequently exposed to other nephrotoxic agents, had a longer duration of therapy, and had higher concentrations of vancomycin during the first 3 days of treatment (C(mean)). The C(mean) was independently associated with early AKI (within 48 h from the onset of therapy) and the duration of vancomycin administration with late AKI | ||
| 520 | |a CONCLUSIONS: AKI occurred in almost 25 % of critically ill patients treated with a continuous infusion of vancomycin. Vancomycin concentrations and duration of therapy were the strongest variables associated with the development of early and late AKI during therapy, respectively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Vancomycin |2 NLM | |
| 650 | 7 | |a 6Q205EH1VU |2 NLM | |
| 700 | 1 | |a Devigili, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ocampos-Martinez, E |e verfasserin |4 aut | |
| 700 | 1 | |a Penaccini, L |e verfasserin |4 aut | |
| 700 | 1 | |a Scolletta, S |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelhadii, A |e verfasserin |4 aut | |
| 700 | 1 | |a De Backer, D |e verfasserin |4 aut | |
| 700 | 1 | |a Beumier, M |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, F |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, J-L |e verfasserin |4 aut | |
| 700 | 1 | |a Taccone, F S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g 41(2013), 4 vom: 08. Aug., Seite 811-20 |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2013 |g number:4 |g day:08 |g month:08 |g pages:811-20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-013-0460-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2013 |e 4 |b 08 |c 08 |h 811-20 | ||